Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

SML3060

Sigma-Aldrich

Panobinostat

≥98% (HPLC)

Sinónimos:

(2E)-N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide, LBH 589, LBH-589, LBH589, N-Hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide, NVP-LBH589

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C21H23N3O2
Número de CAS:
404950-80-7
Peso molecular:
349.43
Número MDL:
MFCD09833242
Código UNSPSC:
12352200
NACRES:
NA.77

Nivel de calidad

100

Ensayo

≥98% (HPLC)

Formulario

powder

color

white to beige

solubilidad

DMSO: 2 mg/mL, clear

temp. de almacenamiento

2-8°C

cadena SMILES

CC1=C(CCNCC2=CC=C(/C=C/C(NO)=O)C=C2)C3=CC=CC=C3N1

InChI

1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+

Clave InChI

FPOHNWQLNRZRFC-ZHACJKMWSA-N

Acciones bioquímicas o fisiológicas

Orally active, potent, cinnamoyl hydroxamate-type pan-histone deacetylase inhibitor with anti-cancer efficacy in vitro and in vivo.
Panobinostat (LBH589) is an orally active, potent, cinnamoyl hydroxamate-type pan-histone deacetylase inhibitor (class I HDAC1/2/3/8 IC50 = 2.5/13.2/2.1/277 nM; IIA HDAC4/5/7/9 IC50 = 203/7.8/531/5.7 nM; IIB HDAC6/10 IC50 = 10.5/2.3 nM, IV HDAC11 IC50 = 2.7 nM) with anti-cancer efficacy in vitro and in vivo.

Palabra de señalización

Danger

Clasificaciones de peligro

Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Eye Dam. 1 - Repr. 1B - Skin Irrit. 2 - STOT RE 2 Inhalation

Código de clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
0000366703
0000366703
0000182918

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Yang Zhang et al.
Frontiers in cell and developmental biology, 8, 652-652 (2020-08-15)
We investigated the therapeutic potential of targeting integrin/FAK-dependent signaling, an adhesion receptor-mediated pathway that has been increasingly linked to non-small cell lung cancer (NSCLC) malignancy. Our analysis of the TCGA cohort showed that a subset of pro-tumorigenic integrins, including α1β1
David I Sandberg et al.
Journal of neurosurgery. Pediatrics, 1-9 (2020-05-02)
Chemotherapy infusions directly into the fourth ventricle may play a role in treating malignant fourth-ventricular tumors. This study tested the safety and pharmacokinetics of short-term and long-term administration of MTX110 (soluble panobinostat; Midatech Pharma) into the fourth ventricle of nonhuman
Shan Su et al.
Frontiers in microbiology, 11, 1584-1584 (2020-08-09)
Invasive fungal infections are an emerging problem worldwide, which bring huge health challenges. Candida albicans, the most common opportunistic fungal pathogen, can cause bloodstream infections with high mortality in susceptible hosts. At present, available antifungal agents used in clinical practice
Peter Atadja
Cancer letters, 280(2), 233-241 (2009-04-07)
The histone deacetylase (HDAC) inhibitors are emerging as a highly useful class of anticancer agents that inhibit the enzyme HDAC involved in the deacetylation of histone and non-histone cellular proteins. The HDAC inhibitor, panobinostat (LBH589, Novartis Pharmaceuticals), achieves potent inhibition
Kenji Fujimoto et al.
Neuro-oncology advances, 2(1), vdaa084-vdaa084 (2020-08-15)
Polyglutamylation is a reversible protein modification that commonly occurs in tumor cells. Methotrexate (MTX) in tumor cells is polyglutamylated and strongly binds to dihydrofolate reductase (DHFR) without competitive inhibition by leucovorin. Therefore, tumor cells with high polyglutamylation levels are supposed
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico